The Impact of Helicobacter pylori Eradication on Long-Term Body Weight Changes, Ghrelin, and Leptin Levels

What Was Tested

Researchers studied Ghrelin in this randomized controlled trial publication.

Thus, their aim was to investigate the long-term effect of H. pylori eradication on changes in ghrelin and leptin levels in a cohort of patients with a largely non-atrophic gastritis.

Why It Was Studied

The association between chronic Helicobacter pylori infection and hormone levels affecting food intake and obesity remains controversial.

Who Took Part

According to the abstract, 72 patients were involved.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

A total of 72 patients meeting the inclusion and exclusion criteria were enrolled between July 2020 and November 2022.

Participants were randomly assigned to two treatment groups (group 1: 14-day regimen with esomeprazole, amoxicillin, and clarithromycin; group 2: 14-day regimen with esomeprazole, amoxicillin, metronidazole, and colloidal bismuth subcitrate).

How the Study Was Run

In design terms this was a randomized study.

Because people in this Ghrelin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The researchers evaluated changes in insulin resistance (HOMA-IR score), body mass index, and serum levels of ghrelin and leptin (ELISA test).

Measurements were conducted at baseline, 2 months, and 1 year following successful H. pylori eradication.

What Was Measured

The association between chronic Helicobacter pylori infection and hormone levels affecting food intake and obesity remains controversial.

Topics PubMed links to this paper include Leptin, Ghrelin, Helicobacter Infections, Helicobacter pylori, Anti-Bacterial Agents, Clarithromycin and Amoxicillin.

The authors tagged it with the keywords Body weight and Eradication.

What This Means in Plain Language

The paper is a randomized study of Ghrelin in 72 patients.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2025 (Digestive diseases (Basel, Switzerland)), a journal based in Switzerland.

More context: the Ghrelin compound page, all human trials.